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Abstract
Gene knockout in murine embryonic stem cells (ESCs) has been an invaluable tool to study gene function in vitro or to
generate animal models with altered phenotypes. Gene targeting using standard techniques, however, is rather inefficient
and typically does not exceed frequencies of 10
26. In consequence, the usage of complex positive/negative selection
strategies to isolate targeted clones has been necessary. Here, we present a rapid single-step approach to generate a gene
knockout in mouse ESCs using engineered zinc-finger nucleases (ZFNs). Upon transient expression of ZFNs, the target gene
is cleaved by the designer nucleases and then repaired by non-homologous end-joining, an error-prone DNA repair process
that introduces insertions/deletions at the break site and therefore leads to functional null mutations. To explore and
quantify the potential of ZFNs to generate a gene knockout in pluripotent stem cells, we generated a mouse ESC line
containing an X-chromosomally integrated EGFP marker gene. Applying optimized conditions, the EGFP locus was disrupted
in up to 8% of ESCs after transfection of the ZFN expression vectors, thus obviating the need of selection markers to identify
targeted cells, which may impede or complicate downstream applications. Both activity and ZFN-associated cytotoxicity
was dependent on vector dose and the architecture of the nuclease domain. Importantly, teratoma formation assays of
selected ESC clones confirmed that ZFN-treated ESCs maintained pluripotency. In conclusion, the described ZFN-based
approach represents a fast strategy for generating gene knockouts in ESCs in a selection-independent fashion that should
be easily transferrable to other pluripotent stem cells.
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Introduction
Since its introduction some 30 years ago, targeted gene editing
in embryonic stem cells (ESCs) has dramatically changed
biomedical research. Although targeted genome engineering was
mainly restricted to murine ESCs for more than two decades,
these cells have served as excellent model systems to study gene
function in vitro or to generate knockout and knock-in mouse
models [1]. Because gene targeting in mouse ESCs using standard
techniques is rather inefficient and typically does not exceed
frequencies of ,10
26 [2], the application of complex positive/
negative selection strategies to isolate targeted clones has been
inevitable. With the availability of induced pluripotent stem cells
(iPSCs) [3] and improved gene targeting technologies, targeted
genome engineering could be transferred to other organisms,
including human cells. For instance, gene targeting in human
ESCs or iPSCs has been successfully accomplished with vectors
based on integrase-deficient lentivirus [4], adeno-associated virus
[5,6], adenovirus [7], baculovirus [8], and non-viral systems, such
as bacterial artificial chromosomes [9]. Furthermore, it has been
established that the frequency of gene targeting at a marker gene
in mouse ESCs could be significantly augmented by creating a
targeted DNA double-strand break with the natural homing
endonuclease I-SceI [10], a concept that could be expanded using
custom-made zinc-finger nucleases (ZFNs) to correct a mutated
EGFP locus [11]. Recent reports demonstrate that ZFNs also
allowed for the generation of human iPSC lines that either
emulate or correct a disease genotype/phenotype [12,13,14].
However, even though many of these novel approaches proved to
increase the gene targeting frequency in pluripotent stem cells
considerably, all of them – even with designer nucleases – were still
dependent on either positive selection markers to enrich for
targeted cells or on screening of large numbers of clones.
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28911ZFNs are the most successful class of designer nucleases up till
now, with one ZFN pair in clinical trials (e.g. NCT01252641). A
ZFN is a functional heterodimer [15], and each subunit consists
of a non-specific nuclease domain derived from the FokI
endonuclease and a specific DNA-binding domain composed of
an engineered zinc-finger array that tethers the enzyme to a
preselected chromosomal site [16]. Upon dimerization of two
ZFN monomers at the target site, the ZFN pair specifically cleaves
the DNA. The resulting double-strand break triggers the cellular
DNA damage response, which can be harnessed for gene
targeting by homologous recombination (HR) or gene knockout
by non-homologous end-joining (NHEJ) [17,18]. Recent progress
in the architectural design of ZFNs have led to both an increase in
nuclease activity and a substantial decrease in nuclease-associated
toxicity [19]. The main improvements include perfected plat-
forms to generate the DNA-binding domains [18,20,21,22],
remodeling of the nuclease dimer interface to prevent homo-
dimerization of two identical ZFN monomers [23,24,25,26,27],
and customized linkers that connect these two main domains
[28,29]. As recently demonstrated for a well-characterized ZFN
that was designed to target the human CCR5 locus, activity at the
target site is at least 3 times more likely than at all off-target sites
combined [30,31].
In this study, we aimed at developing a simple and efficient
method to generate pluripotent knockout cells without the use of
selection systems. While the ZFN technology has been employed
to generate knockouts in a few model organisms and primary cell
types (summarized in [32]), efficient selection-independent ap-
proaches in pluripotent cells have not been described thus far. In
a proof-of-concept approach, we used ZFNs to disrupt the open
reading frame of an X-chromosomally located EGFP gene. We
demonstrate that a knockout could be achieved in up to 8% of
transfected mouse ESCs and that ZFN-treated cells preserved both
normal chromosomal numbers and pluripotency.
Results
ZFN activity and toxicity
For initial characterization, a human osteosarcoma-based cell
line expressing a destabilized EGFP (U2OS.693) was used to assess
the effects of vector dose and nuclease type on gene knockout
activity and ZFN-associated toxicity. The two EGFP-specific ZFN
pairs target position 502 in the EGFP open reading frame [33]
(Fig. 1A) and harbor either a wild-type FokI nuclease domain
(E502-WT) or an obligate heterodimeric (E502-OH) variant
[23,25]. Upon co-transfection of U2OS.693 cells with increasing
Figure 1. Gene knockout in U2OS.693 cells. (A) Schematic of ZFN-mediated knockout. A ZFN pair (ZFNR and ZFNL) designed to target position
502 in the EGFP gene (E502) creates a DNA double-strand break that is sealed by the error-prone non-homologous end-joining (NHEJ) pathway and
hence leads to disruption of the coding sequence. (B) Dose-dependent gene disruption in U2OS.693 cells. U2OS.693 cells that stably express a
destabilized EGFP were transfected with increasing amounts of E502-specific ZFN expression vectors (75–1200 ng). The percentage of EGFP-negative
cells was determined 6 days post-transfection by flow cytometry (n=3; indicated is average and standard deviation). E502-WT, ZFN with wild-type
FokI domain; E502-OH, ZFN with obligate heterodimeric FokI domain. (C) ZFN expression levels. After co-transfection of HEK293T cells with ZFN
expression vectors and pEGFP, cell lysates were probed with antibodies against the HA tag and EGFP. Amount of transfected ZFN plasmids was
75 ng, 300 ng, and 1200 ng. NT, non-transfected cells. (D) Kinetics of EGFP knockout. The graph displays the percentage of EGFP-negative cells (see
B) from day 1 to day 6 post-transfection for two vector amounts (n=3; indicated is average and standard deviation). WT, E502-WT; OH, E502-OH.
doi:10.1371/journal.pone.0028911.g001
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mCherry expression vector as an internal reference, a clear dose
response was observed (Fig. 1B). At day 6 post-transfection, the
percentage of EGFP-negative cells ranged from 1.7–6.5% for
E502-WT and 4.7–10.7% for E502-OH. A transfection with a
control vector (Mock) served to determine the background of
EGFP-negative cells in the culture. Analysis of ZFN expression
confirmed comparable expression levels of E502-WT and E502-
OH (Fig. 1C). Note, as opposed to E502-WT the two subunits of
E502-OH migrate differently in SDS-PAGE [23,25]. Examination
of the kinetics of ZFN-mediated EGFP knockout revealed that
although the percentage of gene knockout was similar at day 3
with ,14% of EGFP-negative cells, this fraction declined by
.50% for E502-WT and ,20% for E502-OH treated cells until
day 6, respectively (Fig. 1D), likely due to the effect of off-target
events in these cells. Together these data show that the efficiency
of ZFN-mediated gene disruption increased with the ZFN vector
dose and decreased with nuclease-associated toxicity, especially
with the WT variant. Although the cytotoxicity was considerably
reduced when using obligate heterodimeric nuclease domains, the
used ZFN pair may still exhibit a considerable degree of unwanted
cytotoxic effects.
ZFN mediated knockout in mouse embryonic stem cells
To assess the feasibility of disrupting a gene in pluripotent stem
cells, the hemizygous mouse ESC line BK4-G3.16 carrying a
single copy marker was generated by targeting integration of an
EGFP gene under control of the hEF-1a promoter into the X-
chromosomal Hprt locus (Fig. 2A). EGFP expression in the BK4-
G3.16 ESC line is high and allows for easy distinction of EGFP-
negative from positive cells by fluorescent microscopy (Fig. 2B)o r
flow cytometry (Fig. 2C).
To knock out marker gene expression, 3610
5 BK4-G3.16 ESCs
were lipofected with increasing amounts of ZFN expression
plasmids (75–1200 ng/well) and an mCherry expression vector
as an internal reference for ZFN production. Flow cytometric
analysis at day 6 post-transfection revealed a clear dose response,
with 0.3–3.2% of EGFP-negative cells when using ZFN variant
E502-WT and 3.3–8% of gene disruption with E502-OH
(Fig. 2D). Because electroporation has been the method of choice
to transfer nucleic acids into mouse ESCs, we compared the
efficiency of this method with lipofection. To this end, 1610
7
BK4-G3.16 cells were co-electroporated with 2–40 mg of E502-
OH expression vector and the mCherry plasmid. The percentage
of EGFP-negative cells was determined between day 2 and 8 post-
transfection (Fig. 2E). Maximal gene disruption activity was
achieved with 20 mg of E502-OH plasmid, leading to ,4% of
EGFP-negative cells at day 2 after electroporation. The percent-
age of EGFP-negative cells slightly decreased during the
observation period of 8 days. Similar results were obtained in a
second mouse ESC line that harbors an EGFP gene integrated into
the Rad54 locus (data not shown). The lower gene knockout
frequency in electroporated ESCs can partially be explained by
the lower overall transfection efficiency, with ,40% mCherry-
positive cells after lipofection and ,30% upon electroporation
(data not shown), respectively.
An evaluation of the kinetics of ZFN-mediated gene disruption
in lipofected ESCs demonstrated that the percentage of EGFP-
negative cells remained stable over the time frame of 9 days
(Fig. 2F). Unlike U2OS.693 cells, however, E502-WT and
E502-OH treated ESCs did not show a similar gene disruption
frequency at early time points. This implies that ESCs may be
more sensitive to ZFN off-target activity and cells exposed to high
E502-WT levels were probably lost early after transfection. To
confirm gene disruption on the genome level, total DNA was
extracted three days after lipofection and the EGFP locus subjected
to analysis with the mismatch-sensitive T7 endonuclease I (T7E1).
The fraction of mutated alleles after exposure of cells to ZFN
E502-OH (Fig. 2G) was in good agreement with the gene
disruption frequency determined by flow cytometry (Fig. 2D).
Finally, analysis of the mCherry expression levels, as a surrogate
marker for ZFN expression, verified that transgene expression in
ESCs is transient and rapidly lost in these fast dividing cells
(Fig. 2H).
In conclusion, similar to the results in the U2OS.693 cells, our
data from the ESCs show that the efficiency of ZFN-mediated
gene disruption was increased when elevated amounts of ZFNs
were expressed, while they were reduced when the more cytotoxic
E502-WT variants were employed. However, the fraction of
knockout cells after lipofection of the ZFN expression plasmids
remained stable, suggesting that cell viability stabilized after the
initial exposure to the nuclease. This observation is in accordance
with the rapid dilution of expression vectors in fast dividing ESCs.
Characterization of ZFN treated embryonic stem cells
To scrutinize the impact of ZFN expression on electroporated
pluripotent mouse cells, two single EGFP-negative ESC clones,
termed 1D1 and 4F6, and two EGFP-positive clones, termed 1B2
and 4C1, were subjected to further analyses. To genotype these
clones, two genomic PCR reactions producing either 228 or 556-
bp amplicons, respectively, that include the E502 target site were
performed (Fig. 3A). The 228-bp fragment contains a unique
TaqI site that overlaps with the ZFN recognition sequence, and
error-prone repair of the ZFN-induced DNA double-strand break
at E502 can lead to disruption of the restriction site. Indeed, the
genomic PCR amplicons generated from the knockout clones were
resistant to cleavage with TaqI endonuclease (Fig. 3B). When the
external primers were used for genomic PCR, a 415-bp fragment
was produced in addition to the expected 556-bp amplicon from
DNA extracted from clone 4F6 (Fig. 3C). Sequencing of these
PCR products confirmed that the EGFP-positive clones 1B2 and
4C1 retained the wild-type sequence (Fig. 3D), while the EGFP
gene in clone 1D1 harbored a 17-bp deletion. The two EGFP
alleles in 4F6 cells contained deletions of 21 and 141 bp,
respectively. These sequencing results for clones 1D1 and 4F6
are consistent with both resistance of the PCR amplicon to TaqI
digestion (Fig. 3B) and the smaller size of the PCR fragments
(Fig. 3B,C).
Because the presence of two EGFP alleles in the 4F6 cells was
rather unexpected, the number of chromosomes per cell was
assessed from ,20 metaphase spreads for each clone after Giemsa
staining. While untreated cells and clone 1D1 cells appeared
normal with 40 chromosomes each (Fig. 4A, B), 4F6 cells
contained between 53 and 90 chromosomes (Fig. 4C). The
increase in chromosome number in 4F6 cells offered an
explanation for the presence of two EGFP alleles. It is not clear
at this point, however, whether the variable number of
chromosomes in 4F6 cells was triggered by ZFN expression or
was a reflection of genomic instability caused by long-term
culturing of the cells [34].
Finally, we assessed whether the ZFN treated cells had
preserved pluripotency. To this end, ZFN-treated ESC clones
1D1 and 4F6 were injected subcutaneously into immunodeficient
mice. Teratomas were removed after 4–8 weeks and analyzed
histologically. Both 1D1 and 4F6 knockout ESCs induced the
formation of teratomas that contained all three germ layers.
However, as opposed to teratomas derived from wild-type ESCs
(Fig. 4D–F) or clone 1D1 cells (Fig. 4G–I), the tumors from 4F6
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to differentiate into all three germ layers (Fig. 4J–L) suggests
either the presence of some few normal diploid cells that were not
detected in the limited number of analyzed metaphase spreads or
that the polyploid state of 4F6 cells did not abrogate the teratoma
formation capability. Together, these data show that ZFNs can be
Figure 2. Gene knockout in mouse embryonic stem cells. (A) Schematic of EGFP locus in BK4-G3.16 cells. The mouse ESC line BK4-G3.16
contains an EGFP gene stably integrated 59 of the endogenous Hprt locus. E502, ZFN target site; hEF-1a, human elongation factor 1a promoter; pA,
poly(A). The primer binding sites and the length (in base pairs) of the PCR amplicon are indicated. (B, C) Assessment of EGFP expression in BK4-G3.16
cells. Marker gene expression was determined by fluorescence microscopy (B) or flow cytometry (C) and was used to identify knockout clones (B) or
to quantify gene disruption frequencies (C). (D, E) Dose-dependent gene disruption in mouse ESCs. BK4-G3.16 cells were lipofected (D) or
electroporated (E) with increasing amounts of E502-specific ZFN expression vectors and an mCherry plasmid as an internal reference. The percentage
of EGFP-negative cells was determined by flow cytometry at day 6 (D; n=3; indicated is average and standard deviation) or at days 2, 6, and 8 (E;
n=1) post-transfection. (F) Kinetics of EGFP knockout. The graph displays the percentage of EGFP-negative cells (see D) from day 2 to day 9 post-
transfection for two vector amounts (n=3; indicated is average and standard deviation). WT, E502-WT; OH, E502-OH. (G) ZFN-induced mutations at
E502 site. After lipofection of BK4-G3.16 with E502-OH expression vector, a genomic PCR fragment encompassing target site E502 was digested with
the mismatch-sensitive T7 endonuclease I (T7E1). The expected lengths (in base pairs) of the T7E1 digestion products are shown on the right.
Asterisks indicate an unspecific DNA fragment. Transfection with a vector control (Mock) was used as a control. (H) Expression kinetics. The graph
displays the percentage of mCherry-positive BK4-G3.16 cells (see D) from day 2 to day 9 post-transfection.
doi:10.1371/journal.pone.0028911.g002
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clones with normal chromosome numbers and preserved pluripo-
tent state can be identified.
Discussion
Gene knockout is a powerful tool for either assessing gene
function and/or permanently modifying the phenotype of a cell
or an entire organism. In selection-free approaches, the ZFN
technology has been successfully used to generate NHEJ-based
knockouts in various model organisms by injecting ZFN-encoding
mRNA in the zygote or early embryo (summarized in [32]),
including fruit fly [35], zebrafish [36,37], rat [38,39] and mouse
[40]. Moreover, the generation of knockout cells has been reported
but application of the ZFN technology has remained restricted to a
few cell types, such as transformed CHO cells [41] or human T
cells [42]. Here, we demonstrated that transient expression of
engineered ZFNs is sufficient to generate a gene knockout in
pluripotent stem cells and that chosen mouse ESC clones
preserved both normal chromosome numbers and pluripotency.
Under optimized conditions, almost 1 out of 10 mouse ESCs
contained a ZFN-induced mutation in EGFP. The highly specific
and efficient mutagenic potential of ZFNs thus presents this simple
one-step approach as a valid alternative to conventional knockout
strategies for researches interested in the generation of knockout
animals or knockout ESC lines. The simplicity of the process is
based on two facts: First, in mammalian cells the NHEJ pathway is
preferred over HR to seal DNA double-stand breaks [43]. Second,
the error-prone nature of the NHEJ repair process frequently
results in insertions/deletions at the ZFN-induced DNA break
[44], which in turn is sufficient to disrupt gene expression. Our
sequencing results are in good agreement with earlier reports and
confirm that ZFN-induced mutations lead to frameshifts and/or
large deletions that abrogate function of the protein of interest
[41,42]. As a consequence, and as opposed to the conventional
HR-based gene knockout approaches in mouse ESCs, the ZFN-
based strategy abrogates the need to design and generate complex
targeting vectors for HR. This greatly simplifies the knockout
protocol and eliminates the usage of selection markers that may
impede or complicate downstream applications.
The construction of the necessary ZFNs to disrupt the locus of
choice may have been a time consuming factor in the past, when
complex selection strategies were necessary to produce ZFNs [22].
The availability of alternative platforms based on pre-assembled
two-finger archives [45,46] reduces the timeframe for generating
functional ZFNs to a few weeks with little hands-on time.
Moreover, alternative designer platforms based on transcription
activator-like effector nucleases (TALENs) [47] will further reduce
the production time to create a functional nuclease to about a
week [48,49,50]. Interestingly, a first side-by-side comparison
between ZFNs and TALENs suggest that the latter may be more
specific and less cytotoxic [51].
The frequency of gene disruption in transformed human U2OS
cells and pluripotent mouse ESCs was dependent on both the
amount of ZFN expression plasmid transfected into the cells and
the nuclease architecture. Likewise, ZFN-associated cytotoxicity
correlated with ZFN dose and the nuclease variant employed. It
has been shown previously that the use of obligate heterodimeric
ZFN variants greatly reduced ZFN-associated toxicity in cultured
cells [23,24,25,26,27] and in zebrafish embryos [52]. Moreover, it
has been shown that obligate heterodimeric ZFN are more specific
than their counterparts with a wild-type FokI nuclease domain
[30]. Here we compared directly the activities and toxicities of
ZFNs in an immortalized cell line and pluripotent stem cells.
Although the knockout frequency of ZFNs with wild-type nuclease
domain and obligate heterodimeric ZFNs may be similar at early
time points, the percentage of EGFP-negative cells after treatment
with E502-WT dropped substantially at later time points,
suggesting massive toxicity. Our data hence emphasize the
importance of employing obligate heterodimeric ZFN variants,
even if ZFNs with optimized DNA-binding domains [22] are
applied, as in this study. Although the use of obligate heterodi-
meric ZFNs reduces off-target cleavage, it cannot be fully
prevented [30,31]. However, the genome of individual ZFN-
targeted ESC clones can be extensively characterized on a
molecular level to identify clones without undesired mutations,
if necessary. While this point might be a minor concern when
generating knockout mice because the animals can be backcrossed
to obtain a pure background, higher specificity of the designer
nucleases that results in a ‘‘clean’’ undisturbed genome is
important if the technology is to be used to knockout genes in
human iPSCs for further use in therapeutic applications [53].
In conclusion, owing to their plasticity and potential to
differentiate in all cell types, pluripotent stem cells represent
Figure 3. Molecular characterization of individual ESC clones.
(A) Schematic of EGFP locus in BK4-G3.16 cells. The primer binding sites
and the lengths (in base pairs) of the generated PCR amplicons are
indicated. (B) Genotyping. The genomic PCR amplicon encompassing
target site E502 was digested with TaqI. The positions of the TaqI-
resistant DNA fragment (228 bp) and a cleavage product (132 bp) are
indicated. (C, D) Sequence of disrupted EGFP alleles. A genomic PCR
expected to produce a 556-bp amplicon was evaluated by agarose gel
electrophoresis (C) and the isolated DNA fragments sequenced (D). The
positions of the expected (556 bp) and the additional DNA fragment
(415 bp) are indicated in (C), the sequences of all alleles are shown in
(D). The ZFN target site (subsites E502L and E502R) is highlighted in
capital letters, the TaqI site in bold letters.
doi:10.1371/journal.pone.0028911.g003
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disorders and can serve as both cellular in vitro models for drug
screening and cell therapeutics in regenerative medicine. As
transient expression of the designer nucleases is sufficient to create
the targeted DNA double-strand break, the ZFNs could also be
applied in the form of mRNA [40]. Because of the high gene
knockout efficiency, selectable markers, which may obstruct
downstream applications, are not necessary to isolate targeted
cells. The simplicity of the described technique will also permit the
knockout of multiple genes, either sequentially or in parallel with
autonomous ZFN pairs [25]. Furthermore, given that efficient
transfection methods for human iPSCs have been established, the
transfer of our findings to the human system should be
straightforward. Future studies will be testing these concepts.
Materials and Methods
ZFN expression plasmids
The EGFP-specific ZFN expression vectors were generated by
subcloning a ZFN pair targeting position 502 of the EGFP open
reading frame (target site 59-ATCCGCCACnnnnnnGAGGACGGC)
[22] into pRK5 vectors [54] that contain either wild-type or the
obligate heterodimeric KV/EA FokI variants [23], respectively. Maps
and sequences of all plasmids are available upon request.
Cell lines
U2OS.693 is a human osteosarcoma based cell line (ATCCH
#HTB-96
TM) [51] that expresses a destabilized EGFP [55]. The
polyclonal cell linewasgenerated by lentiviral transduction followed
by selection with 0.4 mg/ml geneticin [21]. Quantitative PCR
established that cells contain between 3 and 7 copies of the provirus.
U2OS.693 cells were cultured in Dulbecco’s modified Eagle’s
medium(DMEM)supplementedwith10%fetalbovineserum(FBS)
and penicillin/streptomycin (Invitrogen). The murine ESC line
BK4-G3.16 is a derivative of the BK4 line (kindly provided by O.
Smithies, University of North Carolina, Chapel Hill) which
constitutes a subclone of the E14TG2a line (mouse strain
background: 129/Ola) [56]. The construction of the targeting
vector pMP8EGFP, a derivative of pMP8-SKB (kindly provided by
O. Smithies), has previously been described [57]. The scaffold of the
vector enables targeting of the murine X-chromosomal 59-deleted
Hprt locus. Homology-directed integrationfunctionallyreconstitutes
Figure 4. Assessment of metaphase chromosomes and pluripotency. (A–C) Chromosome analysis. Metaphase spreads of BK4-G3.16 cells
were stained with Giemsa. A representative picture of ,20 analyzed metaphase spreads per clone is shown. (D–L) Assessment of pluripotency. ZFN-
treated BK4-G3.16 cells were injected subcutaneously into immunodeficient mice and teratomas removed after 4–8 weeks. Histological analysis using
hematoxylin/eosin staining revealed tissues derived from ectoderm (D, G, J), mesoderm (E, H, K) and endoderm (F, I, L). Scale bars=100 mm for (D–G)
and 50 mm for (H–L).
doi:10.1371/journal.pone.0028911.g004
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hypoxanthine, aminopterin, and thymidine (HAT). At the same
time, the EGFP reporter gene under control of the human
elongation factor 1a (hEF-1a) promoter was introduced 59 of the
Hprt locus in the same orientation. After targeting and expansion,
counting the chromosome number for clone BK4-G3.16 revealed 7
out of a total of 11 metaphase plates displaying the mouse-specific
number of 40 chromosomes (overall distribution: 26–41 chromo-
somes). ESC culture techniques have been described previously
[58]. Briefly, BK4-G3.16 cells were maintained on mitomycin C-
inactivated mouse embryonic fibroblast feeder layers in DMEM
supplemented with 15% ESC-tested FBS (PANBiotech), penicillin/
streptomycin, 0.1 mM ß-mercaptoethanol, 2 mM L-glutamine,
0.1 mM non-essential amino acids and 1:100 LIF produced by
recombinant 8/24 720 LIF-D CHO cells [59].
Transfection and Western blotting
For EGFP knockout, U2OS.693 cells in 12-well plates were
transfected using the calcium phosphate precipitation method [54]
with 75–1200 ng of ZFN expression plasmids, 100 ng of
pRK5.mCherry [51] as an internal reference for transfection
efficiency, and pUC118 to 1.6 mg. BK4-G3.16 cells were transfect-
ed using Lipofectamine 2000 reagent (Invitrogen) according to the
manufacturer’s protocol. Briefly, the day before transfection 3610
5
cells were seeded into a 12-well plate in 1 ml of growth medium
without antibiotics. For each sample 1.6 mg of DNA cocktail (as
above) was mixed with 5 ml of Lipofectamine 2000. Electroporation
of BK4-G3.16 cells was performed as described elsewhere [58].
Briefly, 2–10610
6 cells were resuspended in 400 ml DMEM for
electroporation (400 V/125 mF; BioRad GenePulser
TM) with 2–
40 mg of ZFN expression plasmids. At the indicated time points, the
percentages of EGFP-negative and mCherry-positive cells were
determined by flow cytometry (FACSCalibur; BD Biosciences). The
graphs always display the absolute fraction of EGFP-negative cells,
i.e. without background subtraction or normalization for transfec-
tionefficiency.For Westernblot analysis,HEK-293T cells (ATCCH
#CLR-11268
TM) were transfected using polyethyleneimine (PEI)-
mediated transfection as previously described [60] and harvested
after 30 h. Thirty mg of lysate was separated via sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and transferred to
polyvinylidene difluoride membranes. ZFN and EGFP expression
was detected simultaneously with antibodies directed against the
HA tag (NB600-363, Novus Biologicals) and EGFP (MAB3580,
Millipore) and visualized by infrared imaging after incubation with
secondary antibodies conjugated with either IR-Dyes 680 or
800CW (LI-COR Biosciences).
Genotyping
An amplicon encompassing a 556-bp fragment of the EGFP gene
wasproduced byPCRusing100 ngof genomic DNAasa template,
along with 10 mM of each primer #154 59-ctacggcaagctgaccctgaa
and #598 59-gaactccagcaggaccatgt), 10 mM dNTPs, and 0.5 U of
Phusion High-FidelityDNAPolymerase (Finnzymes)in16reaction
buffer for 30 cycles. The generated products were separated by gel
electrophoresis, extracted using QIAquick Gel Extraction kit
(Qiagen), and subjected to sequencing. The T7 endonuclease I
(T7E1) assay was performed as described previously [51]. In brief,
100 ngofthepurified 556-bpPCRamplicon(seeabove)wasmelted
and re-annealed to allow the formation of heteroduplex DNA,
treated with 5 U of T7E1 (New England BioLabs) for 20 min at
37uC, and separated on a 2% agarose gel. For TaqI-based
genotyping, the 556-bp EGFP-specific amplicon was subjected to
a nested PCR using primers #850 59-atcgacttcaaggaggacggc and
#597 59-ggtgctcaggtagtggttgtc. The resulting 228-bp fragment was
purified using QIAquick PCR purification kit (Qiagen), followed by
digestion with TaqI restriction enzyme (NEB).
Analysis of metaphase chromosomes and teratoma
formation assay
Metaphase spreads were prepared as described previously [61]
and an average of 20 spreads was analyzed after Giemsa staining.
Teratoma assays were performed as previously described [62].
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